Dimerix Completes Enrolment In Phase 3 Trial Of DMX-200 In Focal Segmental Glomerulosclerosis

Dimerix has completed adult enrollment in its pivotal ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis, dosing the 286th patient in a randomized, double‑blind, placebo‑controlled study assessing DMX‑200 (120 mg twice daily) on top of ARB therapy with primary endpoints of proteinuria reduction and eGFR slope over two years. The program has passed seven independent Data Monitoring Committee reviews with no safety concerns; of 69 patients who completed the two‑year treatment period, 65 (94%) entered the open‑label extension, and pediatric recruitment continues as an independent cohort. After PARASOL data supporting proteinuria as a surrogate endpoint, Dimerix and U.S. partner Amicus plan to seek FDA feedback on proposed endpoints before a blinded ACTION3 analysis, and the company says it has sufficient cash to fund the trial; DXB.AX closed at AU$0.60, up 0.83%.

Analysis

Dimerix has completed adult enrolment in the ACTION3 pivotal Phase 3 trial after dosing its 286th patient in a multicenter, randomized, double-blind, placebo-controlled study of DMX-200 (120 mg twice daily) added to standard ARB therapy, with primary endpoints of proteinuria reduction and eGFR slope over a two-year treatment period. The program has cleared seven scheduled independent Data Monitoring Committee reviews with no protocol changes or safety concerns, indicating an absence of emergent safety signals to date.

Of the 69 patients who have completed the full two-year treatment period, 65 (94%) entered the open-label extension, which supports patient retention and tolerability; pediatric recruitment is continuing as an independent cohort that could broaden label scope if successful. Following PARASOL collaboration data that validated proteinuria as a surrogate endpoint, Dimerix and U.S. partner Amicus plan to seek FDA feedback on proposed endpoints prior to conducting a blinded analysis of ACTION3 data, making regulatory engagement the next critical milestone.

Dimerix reports a strong cash position to fund ongoing operations and the ACTION3 trial, while DXB.AX closed at AU$0.60 (up 0.83%) and has traded between AU$0.30 and AU$0.78 over the past year, signaling modest market reaction so far and a wide historical price range that implies volatility around upcoming clinical and regulatory catalysts.

Key Decisions for Investors

• Consider initiating or modestly increasing a size-constrained speculative position to capture potential upside from positive Phase 3 outcomes and regulatory acceptance of proteinuria as a surrogate,
• Monitor the timing and content of FDA feedback on proposed endpoints and the planned blinded ACTION3 analysis as the primary near-term catalysts that will materially affect the development path,
• Maintain risk controls and be prepared to reduce exposure if future DMC reviews or the blinded analysis reveal safety or efficacy issues despite current clearances,
• Watch pediatric cohort recruitment progress and company cash runway disclosures for dilution risk or the need for additional financing that could impact equity value